Establishing commercial success with an effective evidence-generation strategy

Regardless of company size, stage or therapeutic area, a strategic evidence-generation plan is essential to pharmaceutical companies throughout the drug development cycle; from identifying strong clinical endpoints to designing studies that promote patient engagement. There are many opportunities for failure along this path, including a lack of a thoughtfully planned and integrated study pipeline or poorly designed studies that don’t meet the evidence requirements demanded by the FDA, investors, payers and other stakeholders. These can be costly and can result in significant long-term impacts on a product’s evidence portfolio, regulatory approval, adoption rate and reimbursement opportunities.  

Join Baker Tilly for an informative webinar where our team of life sciences professionals will discuss the framework for how to develop effective evidence-generation strategies that address gaps in your organization's current research portfolio. In addition to understanding this framework, we will discuss how to understand knowledge gaps, identify opportunities for collaboration, and discover thoughtful questions to raise about your organization's own evidence-generation strategy.   

Who should attend 

• C-Suite professionals, presidents, vice presidents, management and other leaders of life sciences organizations 

Presenters 

• Grace Macalino, PhD, MPH, Director 
• Meg Glancey, MSPH, Manager 
• Allison Catherino, PhD, Head, US Medical Affairs, Fertility and Endocrinology, EMD Serono 

Learning objectives 

• Outline the importance of an effective evidence-generation strategy 
• Describe how to develop effective evidence-generation strategies  
• Recognize how to identify internal and external stakeholders for collaboration